Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $62.50 USD
Change Today -1.88 / -2.92%
Volume 693.0K
RDUS On Other Exchanges
As of 8:10 PM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

radius health inc (RDUS) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/15/15 - $84.64
52 Week Low
09/15/14 - $13.16
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for RADIUS HEALTH INC (RDUS)

Related News

No related news articles were found.

radius health inc (RDUS) Related Businessweek News

No Related Businessweek News Found

radius health inc (RDUS) Details

Radius Health, Inc., a biopharmaceutical company, focuses on developing therapeutics for patients with osteoporosis and other serious endocrine-mediated diseases in the United States. The company’s lead product comprises abaloparatide SC (BA058), a novel synthetic peptide analog of parathyroid hormone-related protein that is in Phase III clinical development for use in the reduction of fractures in postmenopausal osteoporosis; and Abaloparatide-TD, a line extension of abaloparatide-SC in the form of a transdermal patch that has completed Phase II clinical trial, which is used to increase bone mineral density. It is also developing RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer and other estrogen receptor mediated oncology applications, as well as in Phase II proof of concept study for the treatment of vasomotor symptoms; and RAD140, a nonsteroidal selective androgen receptor modulator for the treatment of breast cancer or other conditions. The company has collaborations and license agreements with Nordic Bioscience Clinical Development VII A/S; 3M; Ipsen Pharma SAS; Eisai Co. Ltd; and Lonza Group Ltd. Radius Health, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

25 Employees
Last Reported Date: 03/10/15
Founded in 2003

radius health inc (RDUS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $450.0K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $346.2K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $300.9K
Chief Development Officer
Total Annual Compensation: $321.3K
Compensation as of Fiscal Year 2014.

radius health inc (RDUS) Key Developments

Radius Health, Inc. Announces Board Changes

Radius Health, Inc. announced that Catherine Friedman, an independent consultant and former Co-Head of the Biotechnology Practice at Morgan Stanley, has been elected to its board of directors. Cathy has also been appointed Chair of the audit committee of the board of directors, replacing Dr. Muenchbach, who has resigned from the Board effective November 3, 2015, but will remain on the Board until that date in order to ensure a smooth transition. Catherine Friedman has served as an independent consultant serving public and private growth companies since 2006. Prior to that, Ms. Friedman held the position of managing director at Morgan Stanley from 1997 to 2006 and head of West Coast Healthcare and co-head of the Biotechnology Practice at Morgan Stanley from 1993 to 2006. She originally joined Morgan Stanley in 1982 and worked in its New York, London and Silicon Valley offices. Since 2007, Ms. Friedman has been a director of XenoPort Inc., where she serves as chair of the audit and governance committee, Enteromedics, where she serves as the chair of the audit committee and governance committee, and in 2014, she joined the board of Theravance and serves on its audit and governance committees. Ms. Friedman joined the board of GSV Capital, a publicly traded investment fund, in 2013 and serves as a member of the valuation committee and as the chair of the audit committee. Ms. Friedman is a member of the board of trustees for Sacred Heart Schools in Atherton.

Radius Health, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Radius Health, Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported loss from operations of $22,278,000 compared to $13,688,000 a year ago. Loss attributable to common stockholders was $22,965,000 or $0.61 per basic and diluted share compared to $16,640,000 or $2.22 per basic and diluted share a year ago. Interest income was $185,000 compared to $5,000 a year ago. For the six months, the company reported loss from operations of $38,593,000 compared to $25,544,000 a year ago. Loss attributable to common stockholders was $40,022,000 or $1.08 per basic and diluted share compared to $36,097,000 or $9.11 per basic and diluted share a year ago. Interest income was $290,000 compared to $7,000 a year ago.

Radius Health, Inc. to Report Q2, 2015 Results on Aug 06, 2015

Radius Health, Inc. announced that they will report Q2, 2015 results at 10:54 PM, GMT Standard Time on Aug 06, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RDUS:US $62.50 USD -1.88

RDUS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RDUS.
View Industry Companies

Industry Analysis


Industry Average

Valuation RDUS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 13.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RADIUS HEALTH INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at